Lack of evidence for a harmful effect of sodium-glucose co-transporter 2 (SGLT2) inhibitors on fracture risk among type 2 diabetes patients: a network and cumulative meta-analysis of randomized controlled trials.
about
Blood pressure control in type 2 diabetic patients.Safe and pragmatic use of sodium-glucose co-transporter 2 inhibitors in type 2 diabetes mellitus: South Asian Federation of Endocrine Societies consensus statement.Canagliflozin in the treatment of type 2 diabetes: an evidence-based review of its place in therapy.Acid-base and electrolyte disorders associated with the use of antidiabetic drugs.Bone effects of canagliflozin, a sodium glucose co-transporter 2 inhibitor, in patients with type 2 diabetes mellitus.Diabetes and kidney disease: the role of sodium-glucose cotransporter-2 (SGLT-2) and SGLT-2 inhibitors in modifying disease outcomes.SGLT2 inhibitor/DPP-4 inhibitor combination therapy - complementary mechanisms of action for management of type 2 diabetes mellitus.A consensus statement for the clinical use of the renal sodium-glucose co-transporter-2 inhibitor dapagliflozin in patients with type 2 diabetes mellitus.Practical Approach to Initiating SGLT2 Inhibitors in Type 2 DiabetesReview article: effects of type 2 diabetes therapies on bone metabolism.Sodium Glucose Cotransporter-2 Inhibition in Heart Failure: Potential Mechanisms, Clinical Applications, and Summary of Clinical Trials.SGLT2 inhibitors: are they safe?Skeletal Fragility in Type 2 Diabetes Mellitus
P2860
Q37566950-4B90818D-138C-41E2-AEAF-BD17327FD5E2Q37588847-D3BDAD2A-27A9-4140-BC9A-AFC469C10B69Q37712199-17176292-8AC1-4725-ADB8-155AD8ECEAACQ38658251-7C0F2F39-EE2B-482B-B4CC-45D082B5751BQ39022309-115A222B-3B1F-4080-9CCF-FEB4B42E9A99Q39039079-D59C58A1-6FC1-4ECA-AEC3-3D3772D3E7B5Q39189383-EF1CAED3-C07B-4B6A-97D0-D3C8B07D157DQ39255188-E2A8F94B-308C-43EC-B94B-E1CF7155D876Q39443326-5A7F2E5D-43BB-48F8-9834-04C331A764FEQ42363966-F2398A3B-62C0-4E77-A468-FD76AF20EB42Q47614541-352BEB39-BBB0-4184-8BF5-F10EDBA0EA81Q47642298-2ED74773-45BB-4D2F-A72D-0E85B91A5D82Q58725004-73EEEE0D-E851-406B-A26E-792D2D7205FB
P2860
Lack of evidence for a harmful effect of sodium-glucose co-transporter 2 (SGLT2) inhibitors on fracture risk among type 2 diabetes patients: a network and cumulative meta-analysis of randomized controlled trials.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
Lack of evidence for a harmful ...... randomized controlled trials.
@en
type
label
Lack of evidence for a harmful ...... randomized controlled trials.
@en
prefLabel
Lack of evidence for a harmful ...... randomized controlled trials.
@en
P2093
P2860
P356
P1476
Lack of evidence for a harmful ...... randomized controlled trials.
@en
P2093
P2860
P304
P356
10.1111/DOM.12742
P577
2016-07-13T00:00:00Z